We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical

177 hedge funds and large institutions have $4.05B invested in Ultragenyx Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 88 increasing their positions, 32 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

417% more capital inflows, than outflows

Capital inflows: $545M | Capital outflows: $105M

175% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 32

103% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $11.2M

61% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 18

8% more funds holding

Funds holding: 164 → 177 (+13)

2.46% more ownership

Funds ownership: 99.74% → 102.21% (+2.5%)

Holders
177
Holders Change
+13
Holders Change %
+7.93%
% of All Funds
3.82%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
29
Increased
88
Reduced
32
Closed
18
Calls
$22.7​M
Puts
$11.2​M
Net Calls
+$11.5​M
Net Calls Change
+$12.1​M

RARE Hedge Fund Activity: Q1 2019 in Review

177 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2019, worth a combined $4.05B — up 85% from $2.19B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RARE positions and 18 closed out — a net gain of 11 holders — while 88 added to existing stakes and 32 trimmed.

The largest buyer was Capital International Investors, adding an estimated $55.9M. The largest seller was Fidelity Investments, cutting an estimated $24.5M.

  • 177 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2019, up from 164 in Q4 2018.
  • Funds reported $4.05B of Ultragenyx Pharmaceutical stock for Q1 2019, up 85% quarter-over-quarter.
  • 29 funds opened new Ultragenyx Pharmaceutical positions in Q1 2019 and 18 closed out, a net change of +11 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q1 2019 was Capital International Investors, an estimated $55.9M added.
  • The largest Ultragenyx Pharmaceutical seller in Q1 2019 was Fidelity Investments, an estimated $24.5M sold.

Based on aggregated 13F filings for Q1 2019.